# AstraZeneca’s Vaxzevria COVID-19 vaccine approved in Japan

- Link: https://www.directorstalkinterviews.com/astrazenecas-vaxzevria-covid-19-vaccine-approved-in-japan/412991298
- Published: 2021-05-21T07:34:19+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
COVID-19 vaccine, _Vaxzevria_ (ChAdOx1-S [Recombinant])_,_ formerly AZD1222, has
been granted a special approval for emergency use in Japan for active immunisation
of individuals aged 18 years and older, to prevent COVID-19 caused by SARS-CoV-2.

The Japanese Ministry of Health, Labour and Welfare granted the approval based on
positive Phase III efficacy and safety data from the Oxford University-led clinical
trial programme in the UK, Brazil and South Africa, and a Phase I/II trial in Japan.

Japan’s Pharmaceuticals and Medical Devices Agency recommends that the use of _Vaxzevria_
should be limited to adults and administered intramuscularly as two 0.5 mL doses
given four to 12 weeks apart, with an interval greater than eight weeks being preferable
to maximise its efficacy. This dosing regimen was shown in clinical trials to be
well-tolerated and effective in preventing symptomatic COVID-19, with no severe 
cases and no hospitalisations more than 14 days after the second dose.^(1)

> **Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said**: “We
> continue to expand global access to our vaccine and today’s approval brings us
> one step closer to providing _Vaxzevria_ to the people of Japan who urgently need
> protection from coronavirus. We are proud to have produced a vaccine for the world,
> which is playing a leading role in the global fight against the pandemic, with
> more than 400 million doses now supplied by AstraZeneca and sub-licensees to 165
> countries.”

Production of the vaccine in Japan is already underway, and the first doses are 
expected to be available in the coming weeks.

The vaccine has been granted a conditional marketing authorisation or emergency 
use in more than 80 countries across six continents and has also received Emergency
Use Listing from the World Health Organization, which accelerates the pathway to
access in up to 142 countries through the COVAX Facility.

_Vaxzevria_ can be stored, transported and handled at normal refrigerated conditions(
two-eight degrees Celsius/36-46 degrees Fahrenheit) for at least six months, and
administered within existing healthcare settings.

AstraZeneca continues to engage with governments, international organisations and
collaborators around the world to ensure broad and equitable access to the vaccine
at no profit for the duration of the pandemic.

Share on:
